Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Author (year)	Design	Number of patients	Sprifermin treatment strategy	Comparison	Follow-up	Outcomes
Lohmander 2014 [18]	RCT	n = 192	SAD/MAD Doses: 10, 30, 100 μg	Placebo	12 months	1, 2, 5, 6, 8, 11
Eckstein 2015 [19]	RCT	n = 168	Injected 3 times over 3 weeks Doses: 10, 30, 100 μg	Placebo	12 months	6, 7
Roemer 2020 [13]	RCT	n = 75	SAD/MAD Doses: 10, 30, 100 μg	Placebo	12 months	9, 10
Dahlberg 2016 [20]	RCT	n = 73	SAD/MAD Doses: SAD: 3, 10, 30, 100 μg; MAD: 3, 10, 30, 100, 300 μg	Placebo	6 months	1, 2, 3, 4
Roemer 2018 [21]	RCT	n = 549	100 μg q6mo, 100 μg q12mo, 30 μg q6mo, 30 μg q12mo	Placebo	6, 12, 18, 24 months	9, 10
Conaghan 2019 [22]	RCT	n = 549	100 μg q6mo, 100 μg q12mo, 30 μg q6mo, 30 μg q12mo	Placebo	2 years	6
Hochberg 2019 [12]	RCT	n = 549	100 μg q6mo, 100 μg q12mo, 30 μg q6mo, 30 μg q12mo	Placebo	2 years/3 years	1, 2, 3, 4, 5, 6, 8, 12
Eckstein 2020 [23]	RCT	n = 516	100 μg q6mo, 100 μg q12mo, 30 μg q6mo, 30 μg q12mo	Placebo	24 months	6, 7

Outcomes: 1. treatment-emergent adverse events (TEAEs), 2. local TEAEs, 3. systemic TEAEs, 4. acute inflammatory reaction (AIRs), 5. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 6. cartilage thickness, 7. ordered values (OVs), 8. cartilage volume, 9. cartilage morphology, 10. bone marrow lesions (BMLs), 11. joint space width (JSW), and 12. minimum joint space width (mJSW)
SAD single ascending dose, MAD multiple ascending dose, q6mo and q12mo sprifermin administered every 6 months and every 12 months, respectively

ISSN: 1478-6362